The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2014 | Phase I study shows AG-221 induces durable remissions in IDH2-mutant acute myeloid leukaemia
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Eytan Stein (Memorial Sloan-Kettering Cancer Center, New York, NY) discusses a Phase I study of AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, in IDH2-mutant acute myeloid leukemia or pre-leukemia (including myelodysplastic syndromes, chronic myelomonocytic leukemia, and myeloproliferative neoplasms).
